Optum notable drugs nearing FDA approval include Anaphylm, Sotyktu, and insulin icodec with decisions expected early 2026.
The FDA is expected to decide on treatments for allergic fungal rhinosinusitis, bipolar I disorder, Hunter syndrome, Leber hereditary optic neuropathy, ovarian cancer, and schizophrenia.
Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...
Zacks Investment Research on MSN
Organon secures FDA approval extending NEXPLANON use to five years
Organon & Co. OGN recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results